Arrowhead Pharmaceuticals, Inc. (ARWR) News
Arrowhead Pharmaceuticals, Inc. (ARWR)
Today's Latest Price: $58.88 USD
Updated Oct 23 4:00pm
Add ARWR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
Filter ARWR News Items
ARWR News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ARWR News From Around the Web
Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Global RNA Interference Market To See Astonishing Growth By 2027|Covid 19 Impact Analysis By Arcturus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Ionis PharmaceuticalsThis research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of |
Arrowhead Pharmaceuticals to Participate in Upcoming Investor ConferencePASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference |
INO, ARWR, ADT and AXL among midday moversGainers: Arrowhead Pharmaceuticals (ARWR) +47%.Eastman Kodak (KODK) +39%.Myomo (MYO) +35%.Inovio Pharmaceuticals (INO) +27%.Renren (RENN) +25%.AMC Networks (AMCX) +22%.Pacific Ethanol (PEIX) +22%.Histogen (HSTO) +21%.Heat Biologics (HTBX) +16%.Ossen Innovation (OSN) +16%.Losers: Novus Therapeutics (NVUS) -17%.ADT (ADT) -13%.American Axle & Manufacturing (AXL) -12%.Forterra (FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (FRAN) -10%.Grupo Supervielle (SUPV) -9%.89bio (ETNB) -9%.Jounce Therapeutics (JNCE) -9%.Empresa Distribuidora (EDN) -6%.... |
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losersGainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.... |
Arrowhead Pharma +10% on encouraging ARO-AAT data in liver diseaseArrowhead Pharmaceuticals (ARWR) jumps 10% on positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 study of ARO-AAT, the second generation investigational RNA interference (RNAi) therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency ((AATD)). The study assesses... |
Why Arrowhead Pharma's Stock Is Trading Higher TodayArrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in … |
Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting 45% Higher TodayArrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher. |
Arrowhead Pharmaceuticals Is A Smart Long-Term OpportunityArrowhead Pharmaceuticals (ARWR) is a clinical-stage company with a broad pipeline of therapies based on its TRiM RNAi platform. While Arrowhead seems some distance from having a commercial drug approval, it is working on a kind of therapy, RNAi, that other companies have successfully commercialized. It also has partnerships where... |
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020 |
Eli Lilly Jardiance Data, And Other News: The Good, Bad And Ugly Of BiopharmaEli Lilly offers positive data for Jardiance in treating cardiovascular issues Eli Lilly (LLY) reported positive data from EMPEROR-Reduced phase III trial. The study aimed to assess the potential of Jardiance in adults with heart failure with reduced ejection fraction, with and without diabetes. The drug candidate was used in... |
